Welcome to ASH 2021!! #ASH21 #IMFASH21
What an amazing and exciting day that kicked off the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. ASH allows doctors from around the world to present various studies happening within the myeloma community. It is truly amazing to see all of the developments within this area.
In addition, I am so grateful that the meeting has a virtual component. The virtual element allows me to experience the meeting without missing a beat! If I had to attend in person, I would not be able to go. By still permitting a virtual platform, I’m able to see all the wonderful presentations that are full of the latest and greatest updates on myeloma. What a great opportunity!
Furthermore, I want to thank the IMF for this occasion. By attending ASH, I can gain more knowledge, which I can then provide to the members of the MM Families Virtual Support Group. https://www.myeloma.org/support-group/mm-families The MM Families Virtual Support group empowers myeloma patients and their caregivers who have young children. By hearing all this newfound knowledge, I hope to encourage them on their journey!
To kick off the first day of ASH, the IMF led a wonderful discussion panel which focused on the following: High-Risk Smoldering Patients; Therapeutic Strategies for Newly Diagnosed Myeloma Patients Both Eligible for Transplant and Not Eligible for Transplant; Tailoring Therapies for First Relapse; Managing Triple-Class Refractory Myeloma, and BCMA-Targeted Therapies.
It was so interesting to hear all the discussions and studies on these various topics. One of the most interesting items that I learned was the development in treating high-risk smoldering multiple myeloma (SMM). Wow! How times have changed! While there is still debate on whether to treat SMM or take the “watch and wait” approach, some of the new studies showed so much promise in treating myeloma early. There was also some interesting data on high-risk patients and tandem transplants, as well as discussion between triplet and quadruplet therapies. In addition, there are so many interesting new studies relating to CAR T.
I’m excited to learn more over the next few days!
Sue Massey, on Twitter: @Mmfamilies_IMF